Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin(University of Oxford), Vicki Adell, Karl Wallendszus, Julie Green, David Z.I. Cherney(University Health Network), Colin Baigent(University of Oxford), Jonathan Emberson(University of Oxford), Christoph Wanner(Universitätsklinikum Würzburg), Masaomi Nangaku(The University of Tokyo), David Preiss(Medical Research Council), Takashi Kadowaki(Toranomon Hospital), Adeera Levin(University of British Columbia), Katherine R. Tuttle(Providence Regional Medical Center Everett), Xavier Rosselló(Spanish National Centre for Cardiovascular Research), Dominik Steubl(Boehringer Ingelheim (Germany)), Rajat Deo, WG Herrington(Boehringer Ingelheim (Germany)), Emily Sammons(University of Oxford), Rizna Abdul Cader(Boehringer Ingelheim (Germany)), MZ Abdul Wahab, AK Cheung, Talal Abdulsamad, Martin Landray(Gentofte Hospital), Roberto Pontremoli(Ospedale Policlinico San Martino), Shinichi Goto, Aldo P. Maggioni(Health Care Foundation), Richard Haynes, Riaz Rahman, Siegfried Seidi(University of Oxford), Sharirose Abat(University of Oxford), P Achiri(University of Oxford), J Li(Shandong University), Wenjun Liu(Liaoning University of Traditional Chinese Medicine), Zhihong Liu(Chinese Academy of Sciences), NK Abdullah, Dandan Zhu, MI Abdul Hafidz, LS Hooi, A A Adeleke, PK Judge, Masami Abe(University of Oxford), W. Grant Stevens, Sarah Acheampong, Ned Abraham(University of Oxford), KJ Mayne, SYA Ng, Michaela Petrini(University of Oxford), JA Acosta, Michael Hill(University of Ottawa)
The Lancet Diabetes & Endocrinology
December 4, 2023
Cited by 94


Related Papers